Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following <scp>Two‐Dose SARS</scp>–<scp>CoV</scp>‐2 Messenger <scp>RNA</scp> VaccinationCaoilfhionn M Connolly, Julie J. Paik, William A. Werbel et al.|Arthritis & Rheumatology|2021Cited by 116
SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19Brian J. Boyarsky, William A. Werbel, Iulia Barbur et al.|Transplantation|2021Cited by 25